Replies to post #231247 on Biotech Values

[vinmantoo]

Thanks Dew, and good news for us EXEL shareholders.

Here is the SEC filing from EXEL, which I found form your link to twitter.

https://ir.exelixis.com/static-files/87164201-5932-4f38-9c82-c2d1ec1f728e

I was thinking about buying more EXEL but didn't pull the trigger. I did buy some more today.

[DewDiligence]

Opdivo/Cabometyx BLA/NDA for RCC combination therapy has 2/21/21 PDUFA (with FDA priority review):

https://www.businesswire.com/news/home/20201019005198/en

Since the treatment regimen, from the CHECKMATE-9ER study, is a combination of a biologic (Opdivo) and a small-molecule TKI (Cabometyx), the FDA is conducting separate but simultaneous reviews for each component, something you don’t often see.